Xin Lang Cai Jing·2026-01-22 10:13Core Viewpoint - The approval of the drug by the National Medical Products Administration marks a significant milestone for the company, indicating its successful entry into the market for critical care medications [1] Group 1: Drug Approval and Indications - The company's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval for the registration of the drug, which is a formulation of dexmedetomidine injection [1] - The approved indications for the drug include the restoration of blood pressure in acute hypotensive states, auxiliary treatment for cardiac arrest, and maintenance of blood pressure post-cardiac arrest [1] Group 2: Research and Development Investment - The drug is developed independently by the company, with a cumulative R&D investment of approximately RMB 8.74 million expected by December 2025 [1] Group 3: Market Potential - According to IQVIA CHPA data, the projected sales of the drug in China for 2024 are estimated to be around RMB 1.811 billion [1]